<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04049552</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20190291H</org_study_id>
    <nct_id>NCT04049552</nct_id>
  </id_info>
  <brief_title>RAPA-Keloid Study of Keloid Regression</brief_title>
  <official_title>Effect of Topical Rapamycin Ointment on Keloid Regression: A Pilot Study in Human Subjects (RAPA-Keloid)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To test whether topical rapamycin regresses established keloids in humans by measuring&#xD;
           surface area and height changes in the scar over time (6 months)&#xD;
&#xD;
        2. To test safety of product and feasibility of conduct for future clinical trial&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This pilot trial will use daily 0.5-1.0 ml applications of 8% RAPA (Rapamycin) in a&#xD;
      petrolatum vehicle to treat established keloid lesions in 5 persons with at least 2 chronic&#xD;
      keloids in similar body regions (greater than 1-year duration). Treatment will be applied&#xD;
      once daily for 6 months. One keloid will receive 8% RAPA ointment and the other keloid will&#xD;
      receive petrolatum-only ointment as a control. Surface areas and height of keloids will be&#xD;
      monitored pre- and post-treatment to evaluate responses.&#xD;
&#xD;
      Keloid surface area and height changes will be measured pre-treatment and thereafter on a&#xD;
      monthly basis using standardized digital photography with a tripod-mounted 8MP Canon S5is&#xD;
      camera and calipers to measure keloid height (37).&#xD;
&#xD;
      Surface areas of all photographed lesions will be measured with Image J&#xD;
      (http://rsbweb.nih.gov/ij/index.html), a public image-processing program that was used to&#xD;
      analyze preliminary data and this study will use the same approach.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 24, 2020</start_date>
  <completion_date type="Actual">May 2, 2021</completion_date>
  <primary_completion_date type="Actual">August 24, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Study participants will serve as their own control, using intervention on one keloid and placebo on the other</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Keloid Surface Area</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Measurement of surface area of keloid</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Keloid Height</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Measurement of height of keloid</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Keloid</condition>
  <arm_group>
    <arm_group_label>RAPA intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rapamycin ointment will be applied to one keloid on the subject</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be applied as a control on one keloid on the subject</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapamycin 8% Ointment</intervention_name>
    <description>A compounded ointment containing 8% rapamycin</description>
    <arm_group_label>RAPA intervention</arm_group_label>
    <other_name>Rapamycin ointment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Petrolatum ointment placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Petrolatum ointment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject must have at least 2 keloid scars (for at least 1 year) in similar body&#xD;
             locations that are easy to reach to apply ointment to&#xD;
&#xD;
          -  Subject will be in good health with all chronic diseases (such as hypertension,&#xD;
             coronary artery disease, etc.) clinically stable&#xD;
&#xD;
          -  Cognitive functioning sufficient to provide informed consent&#xD;
&#xD;
          -  Physically able to apply ointment to keloids daily&#xD;
&#xD;
          -  Able to attend monthly clinic visits for 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of diabetes&#xD;
&#xD;
          -  Subjects taking the following medications: systemic steroid or immunosuppressant&#xD;
             therapy within the past 6 months&#xD;
&#xD;
          -  Local area steroidal treatment within the past 3 months&#xD;
&#xD;
          -  History of allergy to rapamycin of petrolatum-based products&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dean L Kellogg Jr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Health San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Audie L Murphy Memorial Veterans Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 6, 2019</study_first_submitted>
  <study_first_submitted_qc>August 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2019</study_first_posted>
  <results_first_submitted>November 10, 2020</results_first_submitted>
  <results_first_submitted_qc>December 2, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 28, 2020</results_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keloid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Petrolatum</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 30, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/52/NCT04049552/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Each subject enrolled was used as both active intervention and placebo, using 2 keloids on the same subject, color coded to have either rapamycin ointment or placebo ointment applied.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Overall Study Participants</title>
          <description>Rapamycin ointment will be applied to one keloid on the subject, and placebo will be applied to the second keloid on that subject. Keloids will be color coded to match either rapamycin ointment or placebo.&#xD;
Rapamycin 8% Ointment: A compounded ointment containing 8% rapamycin Placebo: Petrolatum ointment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants, each with 2 keloids, served as their own control, with one keloid color coded for active drug and the other for placebo</population>
      <group_list>
        <group group_id="B1">
          <title>Overall Study Participants</title>
          <description>Rapamycin ointment will be applied to one keloid on the subject and placebo will be applied to a second keloid.&#xD;
Keloids will be color coded to match ointment applied&#xD;
Rapamycin 8% Ointment: A compounded ointment containing 8% rapamycin Placebo: Petrolatum ointment</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
        <analyzed>
          <units>Keloids</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Keloid Surface Area</title>
        <description>Measurement of surface area of keloid</description>
        <time_frame>Baseline to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RAPA Intervention</title>
            <description>Rapamycin ointment will be applied to one keloid on the subject&#xD;
Rapamycin 8% Ointment: A compounded ointment containing 8% rapamycin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be applied as a control on one keloid on the subject&#xD;
Placebo: Petrolatum ointment placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Keloid Surface Area</title>
          <description>Measurement of surface area of keloid</description>
          <units>cm2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <units_analyzed>keloids</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>keloids</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.455" lower_limit="0.131" upper_limit="0.735"/>
                    <measurement group_id="O2" value="-0.039" lower_limit="-0.09" upper_limit="-0.0075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Keloid Height</title>
        <description>Measurement of height of keloid</description>
        <time_frame>Baseline to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RAPA Intervention</title>
            <description>Rapamycin ointment will be applied to one keloid on the subject&#xD;
Rapamycin 8% Ointment: A compounded ointment containing 8% rapamycin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be applied as a control on one keloid on the subject&#xD;
Placebo: Petrolatum ointment placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Keloid Height</title>
          <description>Measurement of height of keloid</description>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <units_analyzed>keloids</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>keloids</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1.08" upper_limit="2.04"/>
                    <measurement group_id="O2" value="1.55" lower_limit="1.29" upper_limit="1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.056" lower_limit="0.4" upper_limit="1.54"/>
                    <measurement group_id="O2" value="0.93" lower_limit="0.33" upper_limit="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to 6 months.</time_frame>
      <desc>Any study related adverse event</desc>
      <group_list>
        <group group_id="E1">
          <title>RAPA Intervention</title>
          <description>Rapamycin ointment will be applied to one keloid on the subject&#xD;
Rapamycin 8% Ointment: A compounded ointment containing 8% rapamycin</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo will be applied as a control on one keloid on the subject&#xD;
Placebo: Petrolatum ointment placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dean L Kellogg Jr.</name_or_title>
      <organization>UT Health San Antonio</organization>
      <phone>210-617-5311</phone>
      <email>kelloggd@uthscsa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

